Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Plasma-Cell Myeloma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT00839956
What this trial is testing

Bortezomib and Vorinostat in Treating Patients With Multiple Myeloma Who Have Undergone Autologous Stem Cell Transplant

Who this might be right for
DS Stage I Plasma Cell MyelomaDS Stage II Plasma Cell MyelomaDS Stage III Plasma Cell Myeloma
Fred Hutchinson Cancer Center 31
Early research (Phase 1)WithdrawnNCT00578045
What this trial is testing

UARK 2006-28 Human Cord Blood Transplantation in Advanced Hematological Malignancies

Who this might be right for
Multiple Myeloma
University of Arkansas
Not applicableStudy completedNCT02559583
What this trial is testing

Observational Study in Participants With Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL) in Latin America

Who this might be right for
Multiple MyelomaLeukemiaLymphoid+2 more
Janssen-Cilag Ltd. 5,443
Testing effectiveness (Phase 2)UnknownNCT04762745
What this trial is testing

The Efficacy and Safety of Pomalidomide and Bendamustine With Dexamethasone in Relapsed or Refractory Multiple Myeloma

Who this might be right for
Relapsed, Refractory, Multiple Myeloma
Sun Yat-sen University 56
Not applicableEnded earlyNCT04805203
What this trial is testing

Analysis of the Immune Parameters of COVID-19 Infection in Patients With Multiple Myeloma

Who this might be right for
Multiple MyelomaCovid19
Intergroupe Francophone du Myelome 139
Early research (Phase 1)Study completedNCT04798586
What this trial is testing

MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants With Multiple Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Pfizer 4
Large-scale testing (Phase 3)Study completedNCT00722566
What this trial is testing

Subcutaneous and Intravenous VELCADE in Patients With Previously Treated Multiple Myeloma

Who this might be right for
Multiple Myeloma
Millennium Pharmaceuticals, Inc. 222
Early research (Phase 1)Ended earlyNCT00725062
What this trial is testing

Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant

Who this might be right for
Graft Versus Host DiseaseLeukemiaLymphoma+2 more
Masonic Cancer Center, University of Minnesota 3
Early research (Phase 1)Ended earlyNCT03023527
What this trial is testing

Nivolumab Role in the Treatment of Patients With Refractory or Relapse Multiple Myeloma

Who this might be right for
Multiple Myeloma
PETHEMA Foundation 6
Early research (Phase 1)Study completedNCT04543305
What this trial is testing

PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies

Who this might be right for
Multiple MyelomaAcute Myeloid LeukemiaNon Hodgkin Lymphoma+1 more
Prelude Therapeutics Incorporated 16
Testing effectiveness (Phase 2)Ended earlyNCT00242827
What this trial is testing

Efficacy and Safety of Oral CEP-701 for the Treatment of Patients With Advanced Multiple Myeloma

Who this might be right for
Myeloma
Cephalon
Not applicableLooking for participantsNCT05135351
What this trial is testing

Study Using Prebiotics to Improve Gut Microbiome Diversity After Autologous Cellular Therapy

Who this might be right for
Multiple MyelomaLymphoma
University of Nebraska 30
Very early researchEnded earlyNCT01537861
What this trial is testing

Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Washington University School of Medicine 7
Testing effectiveness (Phase 2)Study completedNCT00683046
What this trial is testing

T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies

Who this might be right for
Acute Myelogenous LeukemiaLymphoid LeukemiaChronic Myelogenous Leukemia+6 more
University of Chicago 204
Not applicableLooking for participantsNCT03127761
What this trial is testing

Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma

Who this might be right for
Multiple Myeloma
Center for International Blood and Marrow Transplant Research 544
Testing effectiveness (Phase 2)WithdrawnNCT01812720
What this trial is testing

Carfilzomib and Dexamethasone in Treating Patients With Multiple Myeloma Who Previously Underwent a Stem Cell Transplant

Who this might be right for
Refractory Multiple MyelomaStage I Multiple MyelomaStage II Multiple Myeloma+1 more
Mayo Clinic
Early research (Phase 1)UnknownNCT05740891
What this trial is testing

AHSCT Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Multiple Myeloma

Who this might be right for
Multiple Myeloma
Zhejiang University 50
Early research (Phase 1)UnknownNCT04727008
What this trial is testing

CXCR4 Modified Anti-BCMA CAR T Cells for Multiple Myeloma

Who this might be right for
Multiple Myeloma
Sichuan University 12
Testing effectiveness (Phase 2)UnknownNCT05055791
What this trial is testing

Evaluate the Safety and Tolerance of SYHX1903 in Patients With Relapsed/Refractory Hematologic Malignancies

Who this might be right for
Acute Myeloid LeukemiaLymphomaMultiple Myeloma
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 312
Not applicableLooking for participantsNCT07309497
What this trial is testing

Pragmatic Geriatric Assessment Before CAR-T or Bispecific Antibody Therapy to Predict Side Effects and Outcomes in Older Patients (GA-ACT Trial)

Who this might be right for
Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), LymphomaCART TherapyBispecific Antibody+1 more
University of Zurich 208
Next Page